Clinical Trials Logo

Clinical Trial Summary

Part 1 of the study determines the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving specific first line treatments for Stage 3 or metastatic non-small cell lung cancer. Part 2 compares the efficacy of inupadenant to placebo when both are combined with carboplatin and pemetrexed for patients that progressed after receiving the same first line treatments for Stage 3 or metastatic non-small cell lung cancer.


Clinical Trial Description

In both Part 1 and Part 2, there are two nonsquamous NSCLC patient populations eligible for the study treatment: 1)patients with Stage III, non-resectable cancer that have received chemoradiotherapy, followed by durvalumab, and then have progressed; 2)patients who have received only first-line immunotherapy with anti-PD-L1 therapy, but no chemotherapy, in the metastatic setting, then progressed. In Part 1, all participants receive open-label inupadenant with standard of care doses of carboplatin and pemetrexed. Carboplatin is given at q3week intervals for no more than 4 cycles; pemetrexed continues at q3week as prescribed by the Investigator. Inupadenant is given orally BID. Dose-limiting toxicities are monitored during the first 21 days of treatment and a modified 3+3 escalation method is utilized to determine the recommended phase 2 dose (RP2D). Imaging and safety and PRO assessments are performed during the treatment and follow-up phase. Treatment continues until progression, withdrawal of consent, start of new anti-cancer treatment, end of study, or death. Part 2 is double-blinded, with subjects randomized 1:1 to receive the RP2D of inupadenant or matched placebo. All subjects receive the carboplatin and pemetrexed per standard of care. Imaging, safety and PRO assessments are performed during the treatment and follow-up phase. Treatment continues until progression, withdrawal of consent, start of new anti-cancer treatment, end of study, or death. In both Parts 1 and 2, blood samples are drawn to further define the pharmacokinetic profile of inupadenant and biosamples are collected for additional exploratory analyses. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05403385
Study type Interventional
Source iTeos Therapeutics
Contact Medical Monitor
Phone +32 71 91 99 33
Email clinical_info@iteostherapeutics.com
Status Recruiting
Phase Phase 2
Start date August 26, 2022
Completion date May 2025

See also
  Status Clinical Trial Phase
Completed NCT01438307 - Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05091190 - Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers N/A
Recruiting NCT04170634 - Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study
Recruiting NCT05339568 - Patient's Whole Process Follow-up Management(HOPE-1)
Recruiting NCT05255302 - De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction Phase 2/Phase 3
Withdrawn NCT04615884 - Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients N/A
Recruiting NCT04846452 - Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC Phase 2
Recruiting NCT05480865 - SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation Phase 1
Terminated NCT03417882 - GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC Phase 2
Recruiting NCT03589339 - NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy Phase 1
Suspended NCT05617313 - Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT06159790 - A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Phase 3